查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1108399

2018-2028 年全球液體活檢市場：標本類型、產品和服務、循環生物標誌物、臨床應用、最終用戶、區域趨勢分析、競爭市場份額和預測

Global Liquid Biopsy Market, By Sampling Type, By Product and Service, By Circulating Biomarker, By Clinical Application, By Application, By End User, By Region Trend Analysis, Competitive Market Share & Forecast, 2018-2028
出版日期: | 出版商: Blueweave Consulting | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

全球液體活檢市場預計將從 2021 年的 26.7 億美元增長到 2028 年底的約 93 億美元，在預測期內以 19.7% 的複合年增長率增長。

對非侵入性技術的需求不斷增加，使用液體標本檢測分子生物標誌物以取代昂貴和侵入性的程序，易用性和微創性，癌症的早期診斷和檢測，新病變液體活檢的優勢，例如表徵癌症，癌症治療的藥物和治療靶點的識別，正在推動市場的增長。

在本報告中，我們調查了全球液體活檢市場並提供市場概況，分析市場增長的各種影響因素、法律和監管環境、技術趨勢、市場規模的轉變和預測、各個細分市場/地區/major 按國家、競爭環境、市場份額、主要公司概況等匯總細分。

內容

第一章研究框架

第二章研究方法

第 3 章執行摘要

第 4 章全球液體活檢市場洞察

  • 工業價值鏈分析
  • DROC 分析
    • 驅動程序
    • 限制因素
    • 機會
    • 任務
  • 技術進步/近期發展
  • 監管框架
  • 波特五力分析

第 5 章全球液體活檢市場概述

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
      • 採血
      • 尿液
      • 唾液
      • 其他
    • 按產品/服務
      • 檢測試劑盒
      • 設備
      • 服務
    • 通過循環生物標誌物
      • 循環腫瘤細胞
      • 循環腫瘤 DNA
    • 按臨床使用
      • 早期癌症篩查
      • 治療方法的選擇
      • 治療監測
      • 復發監測
    • 按用途
      • 癌症
      • 癌症除外
    • 按最終用戶
      • 參考實驗室
      • 醫院
      • 醫生實驗室
      • 學術研究所
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第 6 章。北美液體活檢市場

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
    • 按產品/服務
    • 通過循環生物標誌物
    • 按用途
    • 按臨床使用
    • 按最終用戶
    • 按國家/地區

第 7 章。歐洲液體活檢市場

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
    • 按產品/服務
    • 通過循環生物標誌物
    • 按用途
    • 按臨床使用
    • 按最終用戶
    • 按國家/地區

第 8 章亞太液體活檢市場

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
    • 按產品/服務
    • 通過循環生物標誌物
    • 按用途
    • 按臨床使用
    • 按最終用戶
    • 按國家/地區

第 9 章。拉丁美洲液體活檢市場

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
    • 按產品/服務
    • 通過循環生物標誌物
    • 按用途
    • 按臨床使用
    • 按最終用戶
    • 按國家/地區

第 10 章中東和非洲液體活檢市場

  • 市場規模和預測
  • 市場份額/預測
    • 按樣品類型
    • 按產品/服務
    • 通過循環生物標誌物
    • 按用途
    • 按臨床使用
    • 按最終用戶
    • 按國家/地區

第 11 章競爭格局

  • 主要公司和產品列表
  • 市場份額分析
  • 競爭基準
  • 重大戰略發展（併購/合作）

第 12 章 COVID-19 對全球液體活檢行業的影響

第 13 章公司簡介（公司簡介、財務矩陣、競爭形勢、主要人力資源、主要競爭對手、聯繫人、戰略展望）

  • F. Hoffmann-La Roche Ltd
  • Myraid Genetics
  • QIAGEN
  • Thermo Fisher Scientific Inc
  • Guardant Health
  • MDxHealth SA
  • Exact Sciences Corporation
  • Sysmex Inostics
  • Bio-Rad Laboratories
  • ANGLE plc
  • 其他有力企業

第14章 主要策略建議

Product Code: BWC22224

Global Liquid Biopsy Market to Grow at a CAGR of 19.7% during 2018 - 2028

Global Liquid Biopsy Market is flourishing owing to the rising demand for non-invasive technology that detects molecular biomarkers using liquid samples instead of expensive or invasive procedures along with the advantages of liquid biopsy such as ease of use and minimal invasiveness, early cancer diagnosis and detection, characterization of new lesions, and identification of the drug and therapeutic targets for cancer treatment…

A recent study conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the Global Liquid Biopsy Market was worth USD 2.67 billion in the year 2021. The market is projected to grow at a CAGR of 19.7%, earning revenues of around USD 9.30 billion by the end of 2028. Global Liquid Biopsy Market is booming because of the expanding detection and isolation of circulating tumor DNA, exosomes, and circulating tumor cells. The rapid advancement of digital Polymerase Chain Reaction (PCR) and NGS-based technology has improved liquid biopsy accuracy. It can be used repeatedly to monitor disease progression and is expected to help overcome the limitations of tissue biopsies. Moreover, the constantly evolving pipeline of ctDNA-based liquid biopsy tests, an increasing number of commercialized products, and the potential of ctRNA in determining molecular profiles have all contributed to this segment's dominance. Furthermore, Global Liquid Biopsy Market is one of the most emerging markets that grow continuously owing to the fast integration of new technologies such as the Internet of Things (IoT), Artificial Intelligence (AI), cloud computing, and others. However, high costs associated with R&D capabilities, limited infrastructural facilities, and lower sensitivity of certain liquid biopsies are expected to stymie market growth, in turn, may act as a huge restraining factor for the market growth.

Increasing technological progress

Surging demand for advanced diagnostic equipment, combined with an increase in the number of research laboratories in developing economies, is driving the market growth rate. Furthermore, the rising prevalence of blood cancer around the world is paving the way for market expansion. Moreover, rising R&D spending, particularly in developed and developing economies, will create more lucrative market growth opportunities for medical instruments and devices. The research and development capabilities of pharmaceutical and biopharmaceutical countries for the integration of advanced technologies in healthcare facilities are also boosting market growth rates. As a result, the Global Liquid Biopsy Market is predicted to develop at a significant rate during the forecast period (2022-2028).

Growing Advantages of Liquid Biopsy in the Healthcare Industry

In hospitals, clinics, pathology labs, and other healthcare and research facilities, liquid biopsy tests are conducted to comprehend the molecular elements of cancer. Liquid biopsy is a non-invasive method that uses liquid samples to discover molecular biomarkers without the use of pricy or intrusive procedures. Liquid biopsies provide some advantages that increase the safety and effectiveness of cancer therapy for patients, including their ease of use and low invasiveness, early cancer diagnosis and detection, characterization of new lesions, and discovery of drug & therapeutic targets. This results in offering lucrative opportunities for the Global Liquid Biopsy Market during the forecast period (2022-2028).

Challenge: Vague Reimbursement Situation

The procedure of paying for pricey molecular testing and the knowledge of the several specialists needed to interpret test results and create treatment programs are convoluted and uneven. This is particularly problematic with more expensive modern methods like liquid biopsy. The price of molecular testing services is frequently unknown to doctors, pathologists, and patients until they are paid or billed. Both patients and medical professionals find the confusion disturbing. Additionally, payers' biomarker coverage policies have complex organizational structures that make them challenging to comprehend. While some only pay for the most fundamental tests or those related to certain clinical disorders and genes, others pay for a wide variety of testing. This wide range frequently makes assessing and tracking multiple coverage policies more difficult.

Segmental Coverage

Global Liquid Biopsy Market - By Circulating Biomarker

Based on circulating biomarkers, the Global Liquid Biopsy Market is segmented into Circulating Tumor Cells, Circulating Tumor DNA. The circulating tumor cells segment now has the biggest market share and is likely to continue to do so during the forecast period (2022-2028). This is due to the increased number of clinically important tests with genomic analyses in recent years. Furthermore, due to the rapid development of next-generation sequencing (NGS) technologies in liquid biopsy advancements applied to circulating tumor DNA, circulating tumor DNA is expected to be the fastest-growing segment during the forecast period (ctDNA).

Global Liquid Biopsy Market - By Clinical Application

Based on clinical application, the Global Liquid Biopsy Market is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring. Among these, cancer screening dominates the market. While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible. Moreover, therapy selection is expected to dominate the market share. Therapy selection tests are a type of liquid biopsy in which substrates isolated from bodily fluids such as blood, saliva, or urine are sequenced. This method is less invasive, can be used more frequently, and is less expensive than tests involving tissue sampling via invasive procedures such as surgery.

Impact of COVID-19 on Global Liquid Biopsy Market

The coronavirus disease (COVID-19) has spread worldwide. As a result of the increased number of Coronavirus patients, governments have imposed several rules and lockdowns around the world, affecting the market growth in the early stages of the forecast period. As a result, early detection programs have been halted. Furthermore, there has been a decrease in cancer screenings, visits, therapies, and surgeries, with variations by cancer type and location of service globally, resulting in an increase in cancer morbidity and mortality in 2020. The pandemic has also had an impact on the logistics and supply of cancer diagnostic raw materials and components, as well as other critical commodities used in the production of liquid biopsy. During the COVID-19 pandemic, these factors limit the growth of the liquid biopsy market.

Competitive Landscape

The leading market players in the Global Liquid Biopsy Market are F. Hoffmann-La Roche Ltd, Myraid Genetics, QIAGEN, Thermo Fisher Scientific Inc, Guardant Health, MDxHealth SA, Exact Sciences Corporation, Sysmex Inostics, Bio-Rad Laboratories, ANGLE plc, and other prominent players. The Global Liquid Biopsy Market is highly fragmented with the presence of several manufacturing companies in the country. The market leaders retain their supremacy by spending on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Don't miss the business opportunity in the Global Liquid Biopsy Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Liquid Biopsy Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Liquid Biopsy Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing both qualitative and quantitative data to boost the performance of your business solutions. BWC has built its reputation from the scratch by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Research
  • 2.2. Quantitative Research
  • 2.3. Market Breakdown & Data Triangulation
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents, By Region
  • 2.5. Assumption & Limitation

3. Executive Summary

4. Global Liquid Biopsy Market Insights

  • 4.1. Industry Value Chain Analysis
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunities
    • 4.2.4. Challenges
  • 4.3. Technological Advancement/Recent Development
  • 4.4. Regulatory Framework
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Liquid Biopsy Market Overview

  • 5.1. Market Size & Forecast by Value, 2018-2028
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sampling Type
      • 5.2.1.1. Blood Sampling
      • 5.2.1.2. Urine Sampling
      • 5.2.1.3. Saliva Sampling
      • 5.2.1.4. Other Tissue Fluids Sampling
    • 5.2.2. By Product and Service
      • 5.2.2.1. Assay Kits
      • 5.2.2.2. Instruments
      • 5.2.2.3. Services
    • 5.2.3. By Circulating Biomarker
      • 5.2.3.1. Circulating Tumor Cells
      • 5.2.3.2. Circulating Tumor DNA
    • 5.2.4. By Clinical Application
      • 5.2.4.1. Early Cancer Screening
      • 5.2.4.2. Therapy Selection
      • 5.2.4.3. Treatment Monitoring
      • 5.2.4.4. Recurrence Monitoring
    • 5.2.5. By Application
      • 5.2.5.1. Cancer Applications
      • 5.2.5.2. Non-Cancer Applications
    • 5.2.6. By End User
      • 5.2.6.1. Reference Laboratories
      • 5.2.6.2. Hospitals
      • 5.2.6.3. Physician Laboratories
      • 5.2.6.4. Academic Researchers
      • 5.2.6.5. Others
    • 5.2.7. By Region
      • 5.2.7.1. North America
      • 5.2.7.2. Europe
      • 5.2.7.3. The Asia Pacific
      • 5.2.7.4. Latin America
      • 5.2.7.5. The Middle East and Africa

6. North America Liquid Biopsy Market

  • 6.1. Market Size & Forecast by Value, 2018-2028
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sampling Type
    • 6.2.2. By Product and Service
    • 6.2.3. By Circulating Biomarker
    • 6.2.4. By Application
    • 6.2.5. By Clinical Application
    • 6.2.6. By End User
    • 6.2.7. By Country
      • 6.2.7.1. United States
      • 6.2.7.2. Canada

7. Europe Liquid Biopsy Market

  • 7.1. Market Size & Forecast by Value, 2018-2028
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sampling Type
    • 7.2.2. By Product and Service
    • 7.2.3. By Circulating Biomarker
    • 7.2.4. By Application
    • 7.2.5. By Clinical Application
    • 7.2.6. By End User
    • 7.2.7. By Country
      • 7.2.7.1. Germany
      • 7.2.7.2. United Kingdom
      • 7.2.7.3. Italy
      • 7.2.7.4. France
      • 7.2.7.5. Spain
      • 7.2.7.6. Rest of Europe

8. The Asia Pacific Liquid Biopsy Market

  • 8.1. Market Size & Forecast by Value, 2018-2028
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sampling Type
    • 8.2.2. By Product and Service
    • 8.2.3. By Circulating Biomarker
    • 8.2.4. By Application
    • 8.2.5. By Clinical Application
    • 8.2.6. By End User
    • 8.2.7. By Country
      • 8.2.7.1. China
      • 8.2.7.2. India
      • 8.2.7.3. Japan
      • 8.2.7.4. South Korea
      • 8.2.7.5. Rest of Asia Pacific

9. Latin America Liquid Biopsy Market

  • 9.1. Market Size & Forecast by Value, 2018-2028
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sampling Type
    • 9.2.2. By Product and Service
    • 9.2.3. By Circulating Biomarker
    • 9.2.4. By Application
    • 9.2.5. By Clinical Application
    • 9.2.6. By End User
    • 9.2.7. By Country
      • 9.2.7.1. Brazil
      • 9.2.7.2. Mexico
      • 9.2.7.3. Rest of Latin America

10. The Middle East & Africa Liquid Biopsy Market

  • 10.1. Market Size & Forecast by Value, 2018-2028
    • 10.1.1. By Value (USD Million)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sampling Type
    • 10.2.2. By Product and Service
    • 10.2.3. By Circulating Biomarker
    • 10.2.4. By Application
    • 10.2.5. By Clinical Application
    • 10.2.6. By End User
    • 10.2.7. By Country
      • 10.2.7.1. Saudi Arabia
      • 10.2.7.2. UAE
      • 10.2.7.3. South Africa
      • 10.2.7.4. Rest of Middle East & Africa

11. Competitive Landscape

  • 11.1. List of Key Players and Their Offerings
  • 11.2. Market Share Analysis, 2021
  • 11.3. Competitive Benchmarking, By Operating Parameters
  • 11.4. Key Strategic Development (Merger, Acquisition, Partnership, etc.)

12. Impact of Covid-19 on Global Liquid Biopsy Industry

13. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **

  • 13.1. F. Hoffmann-La Roche Ltd
  • 13.2. Myraid Genetics
  • 13.3. QIAGEN
  • 13.4. Thermo Fisher Scientific Inc
  • 13.5. Guardant Health
  • 13.6. MDxHealth SA
  • 13.7. Exact Sciences Corporation
  • 13.8. Sysmex Inostics
  • 13.9. Bio-Rad Laboratories
  • 13.10. ANGLE plc
  • 13.11. Other Prominent Players

14. Key Strategic Recommendations

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

  • Figure 1: Global Liquid Biopsy Market Segmentation
  • Figure 2: Global Liquid Biopsy Industry Value Chain Analysis
  • Figure 3: Global Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 4: Global Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 5: Global Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 6: Global Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 7: Global Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 8: Global Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 9: Global Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 10: Global Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 11: North America Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 12: North America Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 13: North America Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 14: North America Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 15: North America Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 16: North America Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 17: North America Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 18: North America Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 19: Europe Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 20: Europe Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 21: Europe Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 22: Europe Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 23: Europe Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 24: Europe Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 25: Europe Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 26: Europe Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 27: The Asia-Pacific Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 28: The Asia-Pacific Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 29: Asia-Pacific Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 30: Asia-Pacific Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 31: The Asia-Pacific Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 32: The Asia-Pacific Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 33: The Asia-Pacific Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 34: The Asia-Pacific Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 35: Latin America Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 36: Latin America Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 37: Europe Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 38: Europe Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 39: Latin America Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 40: Latin America Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 41: Latin America Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 42: Latin America Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 43: The Middle East & Africa Liquid Biopsy Market Size, By Value (USD Million), 2018-2028
  • Figure 44: The Middle East & Africa Liquid Biopsy Market Share (%), By Sampling Type, By Value, 2018-2028
  • Figure 45: The Middle East & Africa Liquid Biopsy Market Share (%), By Product and Service, By Value, 2018-2028
  • Figure 46: The Middle East & Africa Liquid Biopsy Market Share (%), By Circulating Biomarker, By Value, 2018-2028
  • Figure 47: The Middle East & Africa Liquid Biopsy Market Share (%), By Application, By Value, 2018-2028
  • Figure 48: The Middle East & Africa Liquid Biopsy Market Share (%), By Clinical Application, By Value, 2018-2028
  • Figure 49: The Middle East & Africa Liquid Biopsy Market Share (%), By End User, By Value, 2018-2028
  • Figure 50: The Middle East & Africa Liquid Biopsy Market Share (%), By Country, By Value, 2018-2028
  • Figure 51: Global Liquid Biopsy Market Share Analysis, 2021

List of Tables

  • Table 1: Global Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 2: Global Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 3: Global Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028
  • Table 4: Global Liquid Biopsy Market Size, By Application, By Value (USD Million), 2018-2028
  • Table 5: Global Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 6: Global Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 7: Global Liquid Biopsy Market Size. By Country, By Value (USD Million), 2018-2028
  • Table 8: North America Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 9: North America Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 10: North America Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028
  • Table 11: 28 North America Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028
  • Table 12: North America Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 13: North America Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 14: 28 North America Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028
  • Table 15: Europe Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 16: Europe Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 17: Europe Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028
  • Table 18: 40 Europe Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028
  • Table 19: Europe Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 20: Europe Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 21: 40 Europe Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028
  • Table 22: The Asia-Pacific Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 23: The Asia-Pacific Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 24: The Asia-Pacific Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028
  • Table 25: The Asia-Pacific Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028
  • Table 26: The Asia-Pacific Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 27: The Asia-Pacific Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 28: The Asia-Pacific Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028
  • Table 29: Latin America Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 30: Latin America Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 31: Latin America Liquid Biopsy Market Size, By Circulating Biomarker, By Value (USD Million), 2018-2028
  • Table 32: Latin America Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028
  • Table 33: Latin America Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 34: Latin America Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 35: Latin America Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028
  • Table 36: The Middle East & Africa Liquid Biopsy Market Size, By Sampling Type, By Value (USD Million), 2018-2028
  • Table 37: The Middle East & Africa Liquid Biopsy Market Size, By Product and Service, By Value (USD Million), 2018-2028
  • Table 38: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Circulating Biomarker, By Value 2018-2028
  • Table 39: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Application, By Value 2018-2028
  • Table 40: The Middle East & Africa Liquid Biopsy Market Size, By Clinical Application, By Value (USD Million), 2018-2028
  • Table 41: The Middle East & Africa Liquid Biopsy Market Size, By End User, By Value (USD Million), 2018-2028
  • Table 42: The Middle East & Africa Liquid Biopsy Market Size (USD Million), By Country, By Value 2018-2028
  • Table 43: List of Key Players and Their Offerings
  • Table 44: Competitive Benchmarking, by Operating Parameters
  • Table 45 F. Hoffmann-La Roche Ltd Company Overview
  • Table 46 F. Hoffmann-La Roche Ltd Financial Overview
  • Table 47 Myraid Genetics Company Overview
  • Table 48 Myraid Genetics Financial Overview
  • Table 49 QIAGEN Company Overview
  • Table 50 QIAGEN Financial Overview
  • Table 51 Thermo Fisher Scientific Inc Company Overview
  • Table 52 Thermo Fisher Scientific Inc Financial Overview
  • Table 53 Guardant Health Company Overview
  • Table 54 Guardant Health Financial Overview
  • Table 55 MDxHealth SA Company Overview
  • Table 56 MDxHealth SA Financial Overview
  • Table 57 Exact Sciences Corporation Company Overview
  • Table 58 Exact Sciences Corporation Financial Overview
  • Table 59 Sysmex Inostics Company Overview
  • Table 60 Sysmex Inostics Financial Overview
  • Table 61 Bio-Rad Laboratories Company Overview
  • Table 62 Bio-Rad Laboratories Financial Overview
  • Table 63 ANGLE plc Company Overview
  • Table 64 ANGLE plc Financial Overview